Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391190
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-25
Brief Title:
Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
A Prospective Single Arm Trial of Concurrent Chemoradiotherapy With Albumin-Bound PaclitaxelCisplatin Followed by PD-1 Inhibitor in Locally Advanced Cervical Cancer
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the safety and efficacy of Albumin-Bound PaclitaxelPlatinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor Sintilimab in locally advanced cervical cancer
Detailed Description:
Patients with pathologically confirmed locally advanced cervical cancer will be treated with concurrent chemoradiotherapy weekly Albumin-Bound Paclitaxel and cisplatin followed by Sintilimab 200mg q3w for 8 cycles
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None